|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117945 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-30 14:34:07 |
|
注册时间: Date of Registration: |
2026-01-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
儿童呼吸道偏肺病毒感染的临床特征及重症预测因素研究:一项基于tNGS的回顾性研究 |
|
Public title: |
Clinical Characteristics and Predictors of Severe Disease in Pediatric Respiratory Metapneumovirus Infection: A Retrospective Study Based on tNGS |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
儿童呼吸道偏肺病毒感染的临床特征及重症预测因素研究:一项基于tNGS的回顾性研究 |
|
Scientific title: |
Clinical Characteristics and Predictors of Severe Disease in Pediatric Respiratory Metapneumovirus Infection: A Retrospective Study Based on tNGS |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
纪俊莉 |
研究负责人: |
程烽 |
|
Applicant: |
Ji Junli |
Study leader: |
Cheng Feng |
|
申请注册联系人电话: Applicant telephone: |
+86 188 9563 6117 |
研究负责人电话: Study leader's telephone: |
+86 138 5903 2130 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2043979413@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
fcheng99@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市晋安区鼓山镇横屿路966号 |
研究负责人通讯地址: |
福建省福州市晋安区鼓山镇横屿路966号 |
|
Applicant address: |
No. 966, Hengyu Road, Gushan Town, Jin‘an District, Fuzhou City, Fujian Province, China |
Study leader's address: |
No. 966, Hengyu Road, Gushan Town, Jin‘an District, Fuzhou City, Fujian Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建省儿童医院 |
||
|
Applicant's institution: |
Fujian Children's Hospital |
||
|
研究负责人所在单位: |
福建省儿童医院 |
||
|
Affiliation of the Leader: |
Fujian Children's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025ETKLRK07013 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省儿童医院伦理委员会 |
||
|
Name of the ethic committee: |
Fujian Children’s Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-25 00:00:00 |
||
|
伦理委员会联系人: |
李小燕 |
||
|
Contact Name of the ethic committee: |
Li Xiaoyan |
||
|
伦理委员会联系地址: |
福建省福州市晋安区鼓山镇横屿路966号 |
||
|
Contact Address of the ethic committee: |
No. 966, Hengyu Road, Gushan Town, Jin‘an District, Fuzhou City, Fujian Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8611 2116 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建省儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fujian Children's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市晋安区鼓山镇横屿路966号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 966, Hengyu Road, Gushan Town, Jin‘an District, Fuzhou City, Fujian Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建省儿童医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Fujian Children's Hospital |
||||||||||||||||||||||
|
Target disease: |
Human metapneumovirus (hMPV) infection |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究的核心目标是通过临床特征、检验结果及tNGS分析,识别偏肺病毒感染患儿中影响病程进展的生物标志物,并进一步构建预测模型,以期为重症肺炎的早期诊断与治疗方案选择提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
The core objective of this study is to identify biomarkers that influence disease progression in children with atypical viral lung infections through clinical features, test results, and tNGS analysis, and to further develop predictive models, with the aim of providing a scientific basis for the early diagnosis and treatment strategy selection of severe pneumonia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
入组标准:年龄≤15岁;呼吸道感染症状明确;tNGS检测明确为hMPV阳性;住院治疗病例,资料完整。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria:Age <=15 years;Clearly defined symptoms of respiratory infection; Confirmed hMPV positive by tNGS detection; Hospitalized cases with complete medical records. |
||||||||||||||||||||||
|
排除标准: |
排除标准:其他明确主因引起住院(如外伤、外科手术);合并其他病原重感染难以分辨者;资料缺失严重者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria:Hospitalization primarily due to other confirmed causes (e.g., trauma, surgical procedures);Co-infection with other pathogens that makes the attribution of severe illness difficult to distinguish;Cases with critically incomplete medical records. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-01 00:00:00至 To 2026-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-30 00:00:00 至 To 2026-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
首先,根据研究方案,我们设计了结构化的电子病例记录表。该CRF详细列出了所有需要收集的变量,包括:1) 患儿基本信息;2) 入院时临床特征;3) 实验室与影像学检查结果;4) 治疗干预措施;5) 疾病转归与结局指标。数据提取由两名独立的临床医生进行,关键变量的评价者间可信度为95%(科恩的κ=0.87)。其次,本研究采用RedCap系统作为EDC平台。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
First, according to the study protocol, we designed a structured electronic case report form (CRF). This CRF detailed all variables to be collected, including: 1) basic patient information; 2) clinical characteristics at admission; 3) laboratory and imaging findings; 4) treatment interventions; and 5) disease progression and outcome measures. Data extraction was performed independently by two clinicians, with an inter-rater reliability of 95% (Cohen's κ = 0.87) for key variables. Second, this study utilized the RedCap system as the electronic data capture (EDC) platform. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |